Trial site
Henry-Joyce Cancer Clinic
Nashville, Tennessee 37232, United StatesNot linked to an institution yet
- 13running trials
- 4closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 23 trials
- Phase 2/33 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Recruiting7 trials
- Active, not recruiting6 trials
- Completed4 trials
- Lead sponsor
- Pfizer9 trials
- Kite, A Gilead Company2 trials
- AstraZeneca1 trial
- Boehringer Ingelheim1 trial
- Exelixis1 trial
- and 3 more
Running trials
Recruiting
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498· Phase 2· Kyntra Bio· Source
Contact: Clinical Trials Office, Vanderbilt-Ingram Cancer Center
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· Phase 1/2· Pfizer· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Pfizer· Source
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· Phase 2/3· Exelixis· Source
Contact: Exelixis Clinical Trials
Active, not recruiting
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· Phase 3· Kite, A Gilead Company· Source
Active, not recruiting
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449· Phase 1· Pfizer· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093· Phase 3· Kite, A Gilead Company· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353· Phase 3· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error